CN1857630A - Proteinuria treating Chinese medicine and its preparing method and use - Google Patents
Proteinuria treating Chinese medicine and its preparing method and use Download PDFInfo
- Publication number
- CN1857630A CN1857630A CN 200610024778 CN200610024778A CN1857630A CN 1857630 A CN1857630 A CN 1857630A CN 200610024778 CN200610024778 CN 200610024778 CN 200610024778 A CN200610024778 A CN 200610024778A CN 1857630 A CN1857630 A CN 1857630A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- drug
- albuminuria
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a kind of proteinuria treating Chinese medicine and its preparation process and use. The proteinuria treating Chinese medicine consists of Chinese medicine extract, water cellulose and carboxylmethyl starch sodium in the weight proportion of 70-100 to 0-110 to 0-4.2 to 0-12.5. The Chinese medicine extract is obtained with imperata cylindrical, astragalus root and/or Chuanxiong rhizome and/or Chinese peashrub root, achyranthes root or teasel root, one of red peony root, etc in certain weight proportion. The proteinuria treating Chinese medicine is suitable for use in treating nephritis.
Description
Technical field
The present invention relates to a kind of anti-albuminuria Chinese medicine, preparation method and purposes.
Technical background
Albuminuria is a common symptom of kidney disease, these sick hormone, immunosuppressant, anticoagulant therapies etc. of adopting of western medical treatment more, and curative effect is not good enough, can produce some side effect simultaneously yet.The Chinese herb decoction treatment has advantage.But for the intractable albuminuria, especially have only urine examination to find albumen in the urine and do not have the albuminuria of special disease performance, onset concealment, course of disease delay often do not have card clinically and can distinguish, bring certain difficulty for the medication of writing out a prescription.
Rhizoma Imperatae water logging agent has significant diuresis through animal experiment proof, and its diuresis may to contain abundant potassium salt relevant with this product; The clinical acute nephritis that is used for the treatment of, effect is better.Chronic nephritis also there is the inducing diuresis to remove edema effect.But the edema that ascites that hepatopathy is caused and heart failure cause does not have tangible inducing diuresis to remove edema effect.Decoct has bacteriostasis to Fu Shi, sonne bacillus in vitro.Other, the treatment acute infectious hepatitis has certain effect.
The Radix Astragali is warm in nature, sweet in the mouth, and QI invigorating is solid plain, diuresis, the removing toxic substances and promoting pus discharge granulation promoting, it is weak to be used for the deficiency of vital energy, and lack of appetite is sugar just, sinking of QI of middle-JIAO, the chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, the exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle is difficult bursts, burst for a long time and do not hold back, the blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst, chronic virtuous inflammation, urine protein, diabetes.The main pharmaceutical component of the Radix Astragali is astragalus polysaccharides (APS) and Radix Astragali saponin class, and effects such as strengthening superficial resistance to stop perspiration, invigorating the spleen and replenishing QI, expelling pus and toxin by strengthening QI and diuretic are arranged, and cardiovascular, blood, kidney, metabolism and immune system etc. are all had effect.In recent years; clinical and experimentation shows; the Radix Astragali has protective effect to diabetes (DM) patient kidney; the mechanism of action of treatment diabetic nephropathy (DN) mainly shows glycometabolic influence, to the influence of hemodynamics change, to the protective effect of glomerular filtration barrier and to somatomedin and cytokine effect etc.
Cheng Xiaochun, Gong Yiyun, people such as Yue Dairong report and adopt the Radix Astragali, Radix Pseudostellariae, the Rhizoma Atractylodis Macrocephalae, Semen Euryales, the dehumidifying of Radix Glycyrrhizae replenishing QI to invigorate the spleen, rise photograph sunken precise and tiny; Semen Cuscutae, Herba Epimedii tonifying the kidney to consolidate the essence close and hide the vital essence that leaks; It is wet that Herba Leonuri, Herba Lycopi, Pheretima are oozed diuretic, and activating blood circulation to dissipate blood stasis improves the microcirculation of kidney.And the modern medicine study large dose Astragalis has the albuminuretic effect of tangible reduction; For anaphylactic disease, Pheretima can solve the desensitization problem of kidney.So all medicines share not only strengthening the body resistance but also eliminating evil taking stopgap measures, can the human body immunity improving function, can help albuminuretic improvement again, can also delay the infringement of kidney merit.So for there being asymptomatic intractable albuminuria all can use, the clinical verification effect is remarkable, can obviously improve curative effect (" practical Chinese medicine magazine ", intractable albuminuria 36 examples, 2002,18 (11) 11 are treated in tonifying speen and tonifying kidney silt ruling by law).
Summary of the invention
The objective of the invention is to provide a kind of anti-albuminuria Chinese medicine, the tablet of especially anti-albuminuria Chinese medicine.Be a kind of clinical use for many years through proved recipe.
Purpose of the present invention also provides a kind of above-mentioned anti-albuminuria preparation method of Chinese medicine.
Another object of the present invention is the purposes that a kind of above-mentioned anti-albuminuria Chinese medicine is provided.
The present invention adopts Rhizoma Imperatae to make monarch drug, function cooling blood for hemostasis, clearing away heat and promoting diuresis; Because of it goes into urinary bladder channel, can clearing away heat and promoting diuresis, heat conduction is descending, and damp-heat in the urinary bladder is pented up and the disease of hyperamization pouring, hematuria is particularly suitable.Cure mainly acute nephritis, hematuria edema, the puckery pain of pyretic stranguria.The Radix Astragali is equipped with Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae is a ministerial drug, QI invigorating invigorating YANG, tonifying the kidney for tranquilization, raise immunity.Be because mostly the urine protein patient deficiency of vital energy, deficiency of the kidney, immunologic function degression, assistant with Radix Achyranthis Bidentatae or/and Radix Dipsaci the kidney invigorating liver, bone and muscle strengthening; Be aided with Radix Paeoniae Rubra and organize blood supply insufficiency in the chronic nephropathy or/and the Radix Paeoniae Alba or/and Rhizoma Chuanxiong etc. are removed than the multi-flavor blood circulation promoting medicine; So be equipped with heat clearing away sterilization, blood circulation promoting and blood stasis dispelling, line water detumescence, relieving constipation diuretic Fructus Liquidambaris again or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica roots etc. reach the unification effect for the treatment of albuminuria for making.Wherein Radix Stephaniae Tetrandrae be good at descending, can clearing away damp-heat, be good at the burnt damp-heat in the urinary bladder of diarrhea especially.Use better efficacy together with the monarch drug Rhizoma Imperatae.
Anti-albuminuria Chinese medicine of the present invention can be extractum or tablet.Anti-albuminuria Chinese medicine of the present invention is made up of following substances: the weight ratio of Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～83.3: 0～126.7: 0～4.2: 0～12.5.When being extractum, the weight ratio of Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～83.3: 0～126.7: 0: 0; When being tablet, the weight ratio of Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～83.3: 0: 2.904～4.2: 8.75～12.5.
Described Chinese medicine extract extracts acquisition by the crude drug of following weight ratio: the weight ratio of monarch drug, ministerial drug, adjuvant drug and accessory drugs is 0.7～1: 0.756～2.08: 0.392～0.56: 0.2015～2.88.Recommending the weight ratio of monarch drug, ministerial drug, adjuvant drug and accessory drugs in the crude drug of above-mentioned weight ratio is 1: 0.756～2.08: 0.392～0.56: 0.2015～2.88.Wherein, described monarch drug be Rhizoma Imperatae, described ministerial drug be the Radix Astragali or/and Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae, described adjuvant drug are Radix Achyranthis Bidentataes Radix Dipsaci, described accessory drugs be Radix Paeoniae Rubra or/and the Radix Paeoniae Alba or/and Rhizoma Chuanxiong or/and Fructus Liquidambaris or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica root.
Among the present invention, especially recommend Chinese medicine extract be by the Chinese medicine crude drug of following weight ratio for better: Rhizoma Imperatae, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi Radix Caraganae Sinicae, Radix Achyranthis Bidentatae, Radix Dipsaci, Radix Paeoniae Rubra, the Radix Paeoniae Alba, rhizome of chuanxiong, Fructus Liquidambaris, Herba Lycopi, Medulla Tetrapanacis, Radix Stephaniae Tetrandrae, river Pennisetum centrasiaticum Tzvel and pubescent angelica root 0.7～1: 0.56～0.8: 0.196～0.28: 0.7～1: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.084～0.12: 0.336～0.48: 0.196～0.28: 0.14～0.2: 0.196～0.28: 0.336～0.48: 0.336～0.48.
Anti-albuminuria preparation method of Chinese medicine of the present invention, system is 58.31～83.3: 0～126.7 with the weight ratio of the crude drug of monarch drug, ministerial drug, adjuvant drug and accessory drugs: 0～4.2: 0～12.5, and thick paste shape extractum is steeped, extracts, filters, is concentrated in 10～25 times of water loggings that add crude drug weight; Perhaps add an amount of cellulose and carboxymethylstach sodium again, stir, make granule, drying, tabletting.Wherein, the weight ratio of Chinese medicine extract and water is 58.31～83.3: 88.69～126.7 in the described thick paste shape extractum.Described extraction is little boiling 0.5～3 hour.
During above-mentioned preparation tablet, the weight ratio of Chinese medicine extract, cellulose and carboxymethylstach sodium is 58.31～83.3: 0: 2.90～4.2: 8.75～12.5 or the weight ratio of described thick paste shape extractum, cellulose and carboxymethylstach sodium be 144～210: 0: 2.90～4.2: 8.75～12.5.
Described cellulose is microcrystalline Cellulose preferably.
Describedly soak, littlely boil and filter, can be divided into secondary and carry out, extraction ratio is higher.As soaked 2～4 hours, add 5～15 times of water gagings for the first time, boil the back and keep little boiling 2 hours, filter; For the second time add 5～10 times of water gagings, boil the back and keep little boiling 1 hour, filter, merge the filtrate of secondary.
The above-mentioned filtrate that obtains is got supernatant, and to be evaporated to density be 1.300～1.350 (80 ℃～85 ℃) thick paste shape extractum, adding an amount of microcrystalline Cellulose and carboxymethylstach sodium stirs, make granule, can add or not add amounts of lubrication after 70 ℃ ± 5 ℃ dryings, the mixing tabletting, show sepia, bitter in the mouth.Also sugar coating again.
Monarch drug described in the method for the present invention be Rhizoma Imperatae, described ministerial drug be the Radix Astragali or/and Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae, described adjuvant drug are Radix Achyranthis Bidentataes Radix Dipsaci, described accessory drugs be Radix Paeoniae Rubra or/and the Radix Paeoniae Alba or/and Rhizoma Chuanxiong or/and Fructus Liquidambaris or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica root.
Recommending the weight ratio of monarch drug, ministerial drug, adjuvant drug and accessory drugs in the crude drug of above-mentioned weight ratio is 1: 0.756～2.08: 0.392～0.56: 0.2015～2.88.Wherein, described monarch drug be Rhizoma Imperatae, described ministerial drug be the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae, described adjuvant drug are Radix Achyranthis Bidentataes Radix Dipsaci, described accessory drugs be Radix Paeoniae Rubra or/and the Radix Paeoniae Alba or/and Rhizoma Chuanxiong or/and Fructus Liquidambaris or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica root.
In the inventive method, especially recommending Chinese medicine extract is to be carried by the Chinese medicine crude drug of following weight ratio obtaining better: Rhizoma Imperatae, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi Radix Caraganae Sinicae, Radix Achyranthis Bidentatae, Radix Dipsaci, Radix Paeoniae Rubra, the Radix Paeoniae Alba, rhizome of chuanxiong, Fructus Liquidambaris, Herba Lycopi, Medulla Tetrapanacis, Radix Stephaniae Tetrandrae, river Pennisetum centrasiaticum Tzvel and pubescent angelica root 0.7～1: 0.56～0.8: 0.196～0.28: 0.7～1: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.084～0.12: 0.336～0.48: 0.196～0.28: 0.14～0.2: 0.196～0.28: 0.336～0.48: 0.336～0.48.
Described filtration can be adopted the filtration of 200 mesh sieves, ultrafiltration etc., merging filtrate; Described concentrating can be that concentrating under reduced pressure is 1.040～1.060 (80 ℃～85 ℃) to relative density, staticly settled 48 hours, getting supernatant, to be evaporated to density be 1.300～1.350 (80 ℃～85 ℃) thick paste shape extractum, adding an amount of microcrystalline Cellulose and carboxymethylstach sodium again stirs, make granule, dry back tabletting, sugar coating, promptly; Also can adopt vacuum drying, lyophilization or spray drying, tabletting.
Anti-albuminuria Chinese medicine of the present invention helps all kinds and the albuminuretic treatment that causes, and especially to light, medium-sized nephritis patient better effects if, and preparation method is easy, is fit to suitability for industrialized production.
The specific embodiment
Following embodiment further specifies the present invention, is limited to content of the present invention but can not limit.
Embodiment 1
Rhizoma Imperatae 2.5kg, Radix Astragali 2.5kg, Radix Et Caulis Acanthopanacis Senticosi 1kg, Radix Achyranthis Bidentatae 1kg, Fructus Liquidambaris 1.5kg and Medulla Tetrapanacis 1kg, 10 times of water gagings were soaked 1 hour, boil the back and keep little boiling 2 hours, excessive, for the second time add 8 times of water gagings, keep little after boiling and boiled excessive mistake 1 hour, merging filtrate is concentrated into thick paste shape extractum 0.7kg.
Embodiment 2
Prescription:
Rhizoma Imperatae 2.5kg Radix Astragali 2kg Radix Stephaniae Tetrandrae 0.7kg
Radix Et Caulis Acanthopanacis Senticosi 0.7kg Radix Caraganae Sinicae 2.5kg Radix Achyranthis Bidentatae 0.7kg
Radix Dipsaci 0.7kg Radix Paeoniae Rubra 0.7kg Radix Paeoniae Alba 0.7kg
Rhizoma Chuanxiong 0.3kg Fructus Liquidambaris 1.2kg Herba Lycopi 0.7kg
Medulla Tetrapanacis 0.5kg river Pennisetum centrasiaticum Tzvel 1.2kg pubescent angelica root 1.2kg
Method for making:
More than ten five tastes, soaked 2～4 hours, add for the first time 10 times of water gagings, boil the back and keep little boiling 2 hours, add for the second time 8 times of water gagings, boil the back and keep little boiling 1 hour, 200 mesh sieves filter, merging filtrate, concentrating under reduced pressure is 1.040～1.060 (80 ℃～85 ℃) to relative density, staticly settles 48 hours, getting supernatant, to be evaporated to density be 1.300～1.350 (80 ℃～85 ℃) thick paste shape extractum 2100 gram, the microcrystalline Cellulose of adding 35～42 grams and 80～125 gram carboxymethylstach sodium stir, and make granule, and 70 ℃ ± 5 ℃ dry back adding lubricants are an amount of.The mixing tabletting, sugar coating promptly gets 1000 gram tablets.Every is 0.3 gram, every bottled 100.This product is a coated tablet, removes coated tablet and shows sepia, bitter in the mouth.
Function cures mainly: vital energy benefiting and the kidney invigorating, improve the glomerular basement membrane permeability, and regulate the kidney blood flow, reduce albumen and discharge.Cure mainly the albuminuria due to all kinds of nephritis and other reasons.
Usage and dosage: oral.Each 4, every day 3 times.Or follow the doctor's advice.
Embodiment 3 acute toxicity tests
Test objective: observe and to be tried thing one twice-daily and give the acute toxic reaction and the situation that produce behind the mice, oral this product maximum dosage-feeding is 1/20g/kg (in a crude drug).
The anti-albumen diaper 0.3g/ sheet (in crude drug 15.5g/ sheet) of embodiment 2
Solution compound method: get 50 of this product (in crude drug 775g), add the suspension (in crude drug) that suitable quantity of water is mixed with 21.5g/ml behind the removal sugar-coat
Laboratory animal is a Kunming mouse, and body weight 19-21 gram, male and female half and half are provided by Chinese Academy of Sciences's Experimental Animal Center.Fasting is 12 hours before the experiment beginning.
Dosage: being tried thing Cmax 21.5g/ml (with crude drug), a twice-daily gives maximum volume 0.8ml/20g (twice dosing interval 6 hours).
Route of administration and method: get 20 of healthy mices, male and female half and half give the test solution that is subjected to of the above-mentioned amount of a twice-daily oral administration gavage, observe the reaction of animals situation after the administration at once and continue and observed seven days, the reaction of record animal toxicity (symptom) and death condition.
The result:
| Sex | Dosage ml/20g | Dosage (in crude drug) ml/kg | Number of animals (only) | Animal positive reaction death toll/sky (only) | Mortality rate % | |||||||
| At once | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |||||
| Female | 1.6 | 1720 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 1.6 | 1720 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Toxic reaction (symptom):
Remove after the administration at once that animal activity has minimizing slightly, recover normal in 30 minutes, observed all healthy survival of animal continuously seven days.
Conclusion: the maximum dosage-feeding of the oral this product of mice one twice-daily is 1720g/kg (in a crude drug).
Embodiment 4 clinical trials
Object of study:
Albuminuria patient 50 examples that albuminuria patient, the especially glomerulonephritis that a variety of causes causes causes, male or female, albumen in the routine urinalysis＞0.3 gram/L, promptly＞urine protein+more than.
All those selected, going into drug of choice, make routine urinalysis and renal function, rejecting renal dysfunction person with the medicine relevant of stopping using in 1-2 week with albuminuria.It is selected to meet above-mentioned requirements person.
The drug dose and the course of treatment:
Anti-3 times/day oral 1-3 months of albumen diaper 4-8 sheet of embodiment 2 are a course of treatment
After the treatment, obey the every 2-4 of anti-protein diaper week check routine urinalysis.With the 1-3 month be a course of treatment, also promptly continue to take medicine after January, chemically examine obvious improver, can suitably reduce dosage, if change not obvious person, must make routine urinalysis and renal function when finish March and treat the comparison of previous crops own control with same amount continuous March.
Observed content:
Obey anti-albumen diaper person: be changed to the master to observe routine urinalysis, simultaneously to might or being ready that accepting comparison person then checks liver, renal function.
Observe the change of main disease when being selected in, and the toxicity after taking medicine.As erythra, heating, gastrointestinal reaction etc.
The standard that curative effect is judged:
Produce effects: the urine protein minimizing differs more than the Lv, as # → Lv, thirty →+, Lv → 0.
Effectively: urine protein reduce differ+more than, as # → thirty, thirty → Lv, Lv →+,+→ 0.
Invalid: urine protein reduce differ not enough+.
The application result of anti-albumen diaper:
General clinical setting when (one) being selected in:
Albumen situation before the treatment:
Routine urinalysis: urine protein: +～Lv is light-duty totally 16 examples;
It is white to urinate: thirty is medium-sized totally 24 examples;
Urine protein: # is totally 10 examples.
Routine urinalysis: urine protein ± be equivalent to 0.1 gram/L ,+being equivalent to 0.3 gram/L, Lv is equivalent to 1 gram/L, and thirty is equivalent to 3 gram/L, and # is equivalent to 6～10 gram/L.
Protopathy:
Focal sections hardening nephritis 3 examples (pathologic finding is all arranged)
Membranous nephropathy 1 example (pathologic finding is all arranged)
IGA nephritis 9 examples (wherein 5 examples are pathological examination)
Lupus nephritis 4 examples
Diabetic nephropathy 6 examples
Renal arteriolosclerosis nephritis 5 examples
Sick 2 examples of myeloma kidney
Constitutional chronic glomerulonephritis 20 examples
(2) treatment situation:
In selected preceding 2 weeks of all MethodsThe cases enrolled, fixing former therapeutic scheme promptly with medicine persons such as hormone or persantins, all continues to use by former dosage, former scheme, increases medicine and dosage no longer in addition, the heavy group of this paper 10 examples, and medium-sized group 6 example all used prednisone and persantin.Prednisone dosage is constant by former scheme, and persantin is 50mg 3 times on the one, does not all use ACEI, because that former scheme albuminuria reduces is dissatisfied, so add with anti-albumen flakes and when not adding this medicine, make own control.All cases take anti-albumen diaper 4-8 sheet/time, three times on the one, all continuous 3 months.The lighter 4# three times on the one; Medium-sized person 6# three times on the one; Heavy type person 8# three times on the one.Except drug withdrawal midway or the mistake person of following up a case by regular visits to.
(3) variation of urine protein sees Table 1 behind the anti-albumen diaper of clothes:
Obey anti-albumen diaper after March concrete variation of urine protein see Table 2:
Table 1 50 examples are albuminuria in various degree, the variation of the back urine protein of getting it filled
| Heavy (10 example) | Medium-sized (24 example) | Light-duty (16 example) | |
| Produce effects (routine number %) | 3/10 30％ | 3/24 12.5％ | 2/16 12.5％ |
| Effectively (routine number %) | 4/10 40％ | 15/24 62.5％ | 10/16 63.50％ |
| Invalid (routine number %) | 3/10 30％ | 6/24 25％ | 4/16 25％ |
| Increase the weight of (routine number %) | 0 | 0 | 0 |
| Various, effective percentage | 70％ | 75％ | 75％ |
| Total effective rate | 73.33％ | ||
The variation of urine protein after table 2 treatment March
| Before the treatment | After treating March | Curative effect | Before the treatment | After treating March | Curative effect | ||
| Light-duty | Medium-sized | ||||||
| 1 | Lv | 0 | Produce effects | 27 | Thirty | Lv | Effectively |
| 2 | + | 0 | Effectively | 28 | Thirty | Lv | Effectively |
| 3 | + | + | Invalid | 29 | Thirty | Thirty | Invalid |
| 4 | + | 0 | Effectively | 30 | Thirty | Lv | Effectively |
| 5 | + | 0 | Effectively | 31 | Thirty | 0 | Produce effects |
| 6 | Lv | + | Effectively | 32 | Thirty | Lv | Effectively |
| 7 | Lv | + | Effectively | 33 | Thirty | Lv | Effectively |
| 8 | Lv | + | Effectively | 34 | Thirty | 0 | Produce effects |
| 9 | + | ± | Invalid | 35 | Thirty | Lv | Effectively |
| 10 | + | 0 | Effectively | 36 | Thirty | Thirty | Invalid |
| 11 | + | 0 | Effectively | 37 | Thirty | Thirty | Invalid |
| 12 | + | + | Invalid | 38 | Thirty | Lv | Effectively |
| 13 | Lv | 0 | Produce effects | 39 | Thirty | Lv | Effectively |
| 14 | + | 0 | Effectively | 40 | Thirty | Lv | Effectively |
| 15 | + | + | Invalid | 41 | Thirty | Lv | Effectively |
| 16 | Lv | + | Effectively | 42 | Thirty | Lv | Effectively |
| Heavy | 43 | Thirty | Thirty | Invalid | |||
| 17 | # | ± | Produce effects | 44 | Thirty | Lv | Effectively |
| 18 | # | + | Produce effects | 45 | Thirty | Lv | Effectively |
| 19 | # | # | Invalid | 46 | Thirty | Lv | Effectively |
| 20 | # | Thirty | Effectively | 47 | Thirty | Thirty | Invalid |
| 21 | # | Thirty | Effectively | 48 | Thirty | Lv | Effectively |
| 22 | # | + | Produce effects | 49 | Thirty | + | Produce effects |
| 23 | # | # | Invalid | 50 | Thirty | Thirty | Invalid |
| 24 | # | # | Invalid | ||||
| 25 | # | Thirty | Effectively | ||||
| 26 | # | Thirty | Effectively |
(4) untoward reaction after taking medicine:
*All patients that take medicine all have no adverse reaction.
*Only one group of 10 example that heavy albuminuria is taken 8 Tid of anti-albumen diaper has two examples too many because of taking medicine, and the back gastrointestinal of taking medicine is slightly with discomfort but can tolerate.
The case that this paper is selected is based on albuminuria, and renal function all belonged to normally in the past, so do the contrast of treatment front and back renal function one by one.But this paper selects 10 routine patients (under the prerequisite that the patient is ready to chemically examine) arbitrarily, does the contrast of treatment front and back hepatic and renal function, routine blood test, and the treatment front and back all belong to normal, and no difference of science of statistics sees Table 3.
The variation of (10 routine patient) hepatic and renal function before and after table 4 treatment
| N | SGPT | SGOT | BUN(mmol/L) | Scr(umol/L) | P | |||||||
| Before the treatment | 10 | 24.1±1.92 | 25.1±2.09 | 5.62±0.39 | 100.5±3.29 | ＞0.05 | ||||||
| After the treatment | 10 | 22.9±1.68 | 24.2±1.57 | 5.57±0.34 | 98.1±3.02 | ＞0.05 | ||||||
| Attached | ||||||||||||
| Sequence number | SGPT(u/L) | SGOT(u/L) | BUN(mmol/L) | Scr(umol/L) | ||||||||
| Before | After | Before | After | Before | After | Before | After | |||||
| 01 | 20 | 22 | 17 | 15 | 4 | 4.1 | 90 | 98 | ||||
| 02 | 31 | 28 | 30 | 25 | 6.3 | 5.2 | 110 | 108 | ||||
| 03 | 16 | 26 | 30 | 18 | 7.0 | 5.4 | 107 | 100 | ||||
| 04 | 30 | 25 | 19 | 26 | 5.5 | 6.5 | 98 | 89 | ||||
| 05 | 27 | 23 | 32 | 30 | 5.5 | 6.4 | 77 | 78 | ||||
| 06 | 32 | 31 | 17 | 27 | 7.1 | 7.0 | 111 | 103 | ||||
| 07 | 18 | 19 | 33 | 31 | 6.3 | 3.6 | 103 | 112 | ||||
| 08 | 20 | 25 | 18 | 23 | 3.8 | 5.2 | 105 | 95 | ||||
| 09 | 19 | 16 | 26 | 22 | 4.5 | 6.3 | 98 | 97 | ||||
| 10 | 28 | 14 | 29 | 25 | 6.2 | 6.0 | 106 | 101 | ||||
| X±SD | 24.1± 1.92 | 22.9± 1.68 | 25.1± 2.09 | 24.2± 1.57 | 5.62± 0.37 | 5.57± 0.34 | 100.5± 3.29 | 98.1± 3.02 | ||||
From clinical observation:
Anti-albumen diaper is better to light, medium-sized albuminuria effect, and is heavy relatively relatively poor, and light-duty is 75%; Medium-sized is 75%; Heavy type is 70%.
This also is appreciated that fully, ill early stage in all kinds of nephritis, pathological change is still light, do not reach fibrosis, the sclerosis of excess of the kidney matter as yet, so add with hoping amelioration of disease in the suitable Chinese medicine, the sclerosis of a nephritis often existing glomerule in ill late period and a matter, fibrosis, extracellular matrix are piled up, and often are difficult to this moment merely with Chinese medicine control or reverse disease.Need take aggregate measures.Various nephropathy diseases are answered the early treatment.
Conclusion: anti-albumen diaper helps all kinds and the albuminuretic treatment that causes, especially to light, medium-sized nephritis patient better effects if.
Claims (10)
1, a kind of anti-albuminuria Chinese medicine, it is characterized in that being made up of following substances: the weight ratio of Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～83.3: 0～126.7: 0～4.2: 0～12.5; Described Chinese medicine extract extracts acquisition by the crude drug of following weight ratio: the weight ratio of monarch drug, ministerial drug, adjuvant drug and accessory drugs is 0.7～1: 0.756～2.08: 0.392～0.56: 0.2015～2.88; Described monarch drug is a Rhizoma Imperatae, described ministerial drug be the Radix Astragali or/and Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae, described adjuvant drug is a Radix Achyranthis Bidentatae or/and Radix Dipsaci, described accessory drugs be Radix Paeoniae Rubra or/and the Radix Paeoniae Alba or/and Rhizoma Chuanxiong or/and Fructus Liquidambaris or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica root.
2, a kind of anti-albuminuria Chinese medicine as claimed in claim 1, it is characterized in that in the described Chinese medicine that the weight ratio of described Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～88.69: 0～126.7: 0: 0.
3, a kind of anti-albuminuria Chinese medicine as claimed in claim 1, it is characterized in that in the described Chinese medicine that the weight ratio of described Chinese medicine extract, water, cellulose and carboxymethylstach sodium is 58.31～83.3: 0: 2.904～4.2: 8.75～12.5.
4, as claim 1,2 or 3 described a kind of anti-albuminuria Chinese medicines, it is characterized in that described Chinese medicine extract is extraction of Chinese medicine crude drug and the acquisition by the following weight ratio: Rhizoma Imperatae, the Radix Astragali, the Radix Et Caulis Acanthopanacis Senticosi Radix Caraganae Sinicae, Radix Achyranthis Bidentatae, Radix Dipsaci, Radix Paeoniae Rubra, the Radix Paeoniae Alba, rhizome of chuanxiong, Fructus Liquidambaris, the Herba Lycopi, Medulla Tetrapanacis, Radix Stephaniae Tetrandrae, river Pennisetum centrasiaticum Tzvel and pubescent angelica root are followed successively by 0.7～1: 0.56～0.8: 0.196～0.28: 0.7～1: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.084～0.12: 0.336～0.48: 0.196～0.28: 0.14～0.2: 0.196～0.28: 0.336～0.48: 0.336～0.48.
5, a kind of a kind of anti-albuminuria preparation method of Chinese medicine as claimed in claim 1, it is characterized in that the weight ratio with the crude drug of monarch drug, ministerial drug, adjuvant drug and accessory drugs is 0.7～1: 0.756～2.08: 0.392～0.56: 0.2015～2.88, add crude drug weight 10～25 times of water loggings bubbles, little boil 0.5～3 hour, filter, be concentrated into thick paste shape extractum; Perhaps add again cellulose with carboxymethylstach sodium, stir, make granule, drying, tabletting and become tablet;
Wherein, the weight ratio of Chinese medicine extract and water is 70～100: 0～1 in the described thick paste shape extractum;
The weight ratio of described thick paste shape extractum, cellulose and carboxymethylstach sodium is 144～210: 0: 2.90～4.2: 8.75～12.5
Described monarch drug be Rhizoma Imperatae, described ministerial drug be the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi or/and Radix Caraganae Sinicae, described adjuvant drug are Radix Achyranthis Bidentataes Radix Dipsaci, described accessory drugs be Radix Paeoniae Rubra, the Radix Paeoniae Alba or/and or/and Rhizoma Chuanxiong or/and Fructus Liquidambaris or/and the Herba Lycopi or/and Medulla Tetrapanacis or/and Radix Stephaniae Tetrandrae or/and the river Pennisetum centrasiaticum Tzvel or/and pubescent angelica root.
6, a kind of anti-albuminuria preparation method of Chinese medicine as claimed in claim 5, it is characterized in that described cellulose is a microcrystalline Cellulose.
7, a kind of anti-albuminuria preparation method of Chinese medicine as claimed in claim 5, it is characterized in that describedly soaking, littlely boil and filter, be divided into secondary and carry out, described crude drug is added 5～15 times of water gagings for the first time, boil the back and keep little boiling 2 hours, filter; For the second time add 5～10 times of water gagings, boil the back and keep little boiling 1 hour, filter, merge the filtrate of secondary; Described concentrate is that the filtrate that obtained is got supernatant to be evaporated to density is 1.300～1.350 thick paste shape extractum, adds an amount of microcrystalline Cellulose and carboxymethylstach sodium and stirs, and makes granule, dry adding afterwards or do not add amounts of lubrication, mixing tabletting; Or sugar coating becomes tablet again.
8, a kind of anti-albuminuria preparation method of Chinese medicine as claimed in claim 5, it is characterized in that described crude drug is the crude drug of following weight ratio: Rhizoma Imperatae, the Radix Astragali, the Radix Et Caulis Acanthopanacis Senticosi Radix Caraganae Sinicae, Radix Achyranthis Bidentatae, Radix Dipsaci, Radix Paeoniae Rubra, the Radix Paeoniae Alba, rhizome of chuanxiong, Fructus Liquidambaris, the Herba Lycopi, Medulla Tetrapanacis, Radix Stephaniae Tetrandrae, river Pennisetum centrasiaticum Tzvel and pubescent angelica root 0.7～1: 0.56～0.8: 0.196～0.28: 0.7～1: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.196～0.28: 0.084～0.12: 0.336～0.48: 0.196～0.28: 0.14～0.2: 0.196～0.28: 0.336～0.48: 0.336～0.48.
9, a kind of anti-albuminuria preparation method of Chinese medicine as claimed in claim 5, it is characterized in that described filtration is that 200 mesh sieves filter or ultrafiltration; Described drying is a vacuum drying, lyophilization or spray drying.
10, a kind of purposes of a kind of anti-albuminuria Chinese medicine as claimed in claim 1 is characterized in that treating the application of the medicine of nephritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100247781A CN100377736C (en) | 2006-03-16 | 2006-03-16 | Proteinuria treating Chinese medicine and its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100247781A CN100377736C (en) | 2006-03-16 | 2006-03-16 | Proteinuria treating Chinese medicine and its preparing method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1857630A true CN1857630A (en) | 2006-11-08 |
| CN100377736C CN100377736C (en) | 2008-04-02 |
Family
ID=37296618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100247781A Active CN100377736C (en) | 2006-03-16 | 2006-03-16 | Proteinuria treating Chinese medicine and its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100377736C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784242A (en) * | 2012-06-15 | 2012-11-21 | 李亚萍 | Decoction medicament for treating damp-heat type proteinuria |
| CN105343230A (en) * | 2015-11-14 | 2016-02-24 | 佟爱华 | Traditional Chinese medicine composition used for treating intractable proteinuria |
| CN111068010A (en) * | 2018-10-19 | 2020-04-28 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating refractory idiopathic membranous nephropathy and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097623A (en) * | 1994-06-18 | 1995-01-25 | 吴开云 | Treatment chronic nephritis, uremic Chinese medicine preparation and preparation method thereof |
-
2006
- 2006-03-16 CN CNB2006100247781A patent/CN100377736C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784242A (en) * | 2012-06-15 | 2012-11-21 | 李亚萍 | Decoction medicament for treating damp-heat type proteinuria |
| CN105343230A (en) * | 2015-11-14 | 2016-02-24 | 佟爱华 | Traditional Chinese medicine composition used for treating intractable proteinuria |
| CN111068010A (en) * | 2018-10-19 | 2020-04-28 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating refractory idiopathic membranous nephropathy and application thereof |
| CN111068010B (en) * | 2018-10-19 | 2021-08-10 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating refractory idiopathic membranous nephropathy and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100377736C (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1931301A (en) | Chinese medicine prepn for treating mastoproliferation and its prepn process | |
| CN1122243A (en) | Medicinal powder for eliminating embolism and invigorating blood circulation | |
| CN1846765A (en) | Kidney benefiting hypoglycemic medicine composition and its prepn process | |
| CN1814208A (en) | Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis | |
| CN1857630A (en) | Proteinuria treating Chinese medicine and its preparing method and use | |
| CN1152707C (en) | pill for treating diarrhea | |
| CN1243561C (en) | Chinese medicine for cancer | |
| CN1188153C (en) | Medicines for treating cancers and tumours | |
| CN1781538A (en) | Chinese medicine preparation for treating mephritis and nephrosis syndrome | |
| CN1772257A (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN1486736A (en) | A Chinese medicinal composition for treating hepatic fibrosis and liver cirrhosis, KANGJINRUANGGAN pill | |
| CN1285354C (en) | Medicine for treating cerebral infarction | |
| CN1169555C (en) | A Chinese medicinal decoction pill for treating hepatitis B | |
| CN101057945A (en) | Traditional Chinese medicine for treating digestive cancer and its producing method | |
| CN1208083C (en) | A Chinese medicinal composition for treating visceral inflammation, toxin and endocrine disturbance | |
| CN1814131A (en) | Chinese medicine for treating astriction and preparing method | |
| CN1868528A (en) | Traditional Chinese medicine prepns. for treating cardiovascular and cerebrovascular diseases | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1857629A (en) | Hematuria treating Chinese medicine and its preparing method and use | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1244339C (en) | Chinese medicine for treating and preventing fatty liver and its preparing process | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |